Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor

Table 1 Clinical characteristics of patients

Clinical characteristics
Age in yrs, as median (range)	54 (25, 82)
Gender, male/female	50/63
Tumor location, head/body, tail	66/47
Tumor diameter, as median (range)	3.8 (1.0, 10.5) cm
Extend of disease, localized/nodal	66/47
Tumor grade, 1/2	101/12
TNM stage, 1, 2/3	66/47
Functional pNET, no/yes	108/5
MPV, as median (range)	11.1 (9.1, 13.8) fL
PLR, as median (range)	130.7 (13.6, 413.3 )
Platelet count, as median (range)	225 (79, 436) × 109/L
Death, no/yes	100/13
Recurrence, no/yes	72/41

MPV: Mean platelet volume; PLR: Platelet lymphoid ratio; pNET: Pancreatic neuroendocrine tumor; TNR: Tumor, nodes, metastases.

Table 2 The relationship between CD42b expression and clinicopathologic characteristics of patients

Factor	CD42b expression		P value
	Negative	Positive
Age in yr			0.157
< 54	33	23
≥ 54	26	31
Gender			0.968
Male	26	24
Female	33	30
Tumor location			0.186
Head	31	35
Body, Tail	28	19
Tumor grade			0.439
1	54	47
2	5	7
TNM stage			0.556
1, 2	36	30
3	23	24
Functional pNET			1.00
No	56	52
Yes	3	2
Platelet count, as × 109/L			0.928
< 225	29	27
≥ 225	30	27
MPV in fL			0.298
< 11.1	32	24
≥ 11.1	27	30
PLR			0.507
< 130.7	31	25
≥ 130.7	28	29

P < 0.05 was statistically significant. pNET: Pancreatic neuroendocrine tumor; MPV: Mean platelet volume; PLR: Platelet lymphoid ratio; TNR: Tumor, nodes, metastases.

Table 3 Univariate Cox regression analyses of overall survival and recurrence-free survival with clinicopathologic characteristics in resectable pancreatic neuroendocrine tumor patients

Factor	OS			RFS
	HR	95%CI	P value	HR	95%CI	P value
Age, < 54/≥ 54	1.790	0.585-5.481	0.308	0.995	0.538-1.840	0.987
Gender, male/female	2.689	0.740-9.770	0.133	0.972	0.526-1.796	0.929
Tumor location, head/body, tail	0.760	0.233-2.482	0.650	1.026	0.531-1.982	0.939
Tumor grade, 1/2	13.403	4.332-41.466	< 0.001	5.509	2.299-13.199	< 0.001
TNM stage, 1, 2/3	8.861	1.960-40.064	0.005	2.892	1.527-5.477	0.001
Functional pNET, no/yes	0.046	0.000-5340.899	0.606	0.412	0.056-3.007	0.382
Platelet count, as × 109/L, < 225/≥ 225	2.497	0.768-8.114	0.128	1.188	0.642-2.201	0.583
MPV in fL, < 11.1/≥ 11.1)	1.442	0.472-4.411	0.521	1.547	0.827-2.893	0.172
PLR, < 130.7/≥ 130.7	1.217	0.409-3.624	0.724	1.043	0.564-1.927	0.894
CD42b expression, negative/positive	6.432	1.425-29.025	0.015	3.203	1.603-6.400	0.001

P < 0.05 was statistically significant. pNET: Pancreatic neuroendocrine tumor; CI: Confidence interval; HR: Hazard ratio; OS: Overall survival; RFS: Recurrence-free survival; MPV: Mean platelet volume; PLR: Platelet lymphoid ratio.

Table 4 Multivariate Cox regression analyses of overall survival and recurrence-free survival with clinicopathologic characteristics in resectable pancreatic neuroendocrine tumor patients

Factor	OS			RFS
	HR	95%CI	P value	HR	95%CI	P value
Tumor grade, 1/2	5.882	1.848-18.719	0.003	3.283	1.345-8.016	0.009
TNM stage, 1, 2/3	5.136	1.062-24.842	0.042	2.366	1.219-4.591	0.011
CD42b expression, negative/positive	4.601	1.004-21.095	0.049	2.893	1.439-5.817	0.003

P < 0.05 was statistically significant. pNET: Pancreatic neuroendocrine tumor; CI: Confidence interval; HR: Hazard ratio; OS: Overall survival; RFS: Recurrence-free survival.